U.S. Inflammatory Bowel Disease Treatment Market Size, Share & COVID-19 Impact Analysis, By Disease Indication (Ulcerative Colitis and Crohns Disease), By Route of Administration (Oral and Injectables), By Drug Class (IL Inhibitors, TNF Inhibitors, Anti-integrin, JAK Inhibitors, Corticosteroids, ASA Drugs, and Others), By Distribution Channel (Hospital Pharmacy and Retail Pharmacy & Other), and Country Forecast, 2023-2030

The U.S. inflammatory bowel disease treatment market size was worth USD 9.37 billion in 2022 and is projected to grow at a CAGR of 5.5% during the forecast period.

Inflammatory Bowel Disease (IBD) is a chronic condition that can be treated but not cured. Symptoms include diarrhea, belly pain, nausea, fever, loss of appetite, fatigue, and sometimes rectal bleeding. According to a study published by the Crohn’s & Colitis Foundation in July 2023, nearly 1 in 100 Americans have inflammatory bowel disease. The burden of this disease is growing in the U.S., with 56,000 new cases diagnosed yearly.

An increase in awareness about this disease among the general population and advancement in diagnostic tools are some reasons leading to an increased diagnosis rate. Moreover, the reimbursement policies offered by the government to reduce the economic burden of patients undergoing treatment are driving the demand for inflammatory bowel disease treatment. The active investments made by market players to accelerate and support the development of pipeline candidates is augmenting market growth.

The outbreak of the COVID-19 pandemic led to slower U.S. inflammatory bowel disease treatment market growth in 2020 due to delays in diagnosis procedures and treatment limitations imposed during the pandemic period.

LATEST TRENDS

Technological Advancements in Inflammatory Bowel Disease Treatment to Boost Market Expansion

The utilization of cutting-edge technology, such as Single-cell RNA sequencing, is aiding healthcare professionals in diagnosing and treating inflammatory bowel disease. High-dimensional technologies, such as Single-cell RNA sequencing and Mass Cytometry, have been employed to analyze intestinal samples taken from patients with Crohn's Disease (CD) or Ulcerative Colitis (UC). The analysis of Single-cell RNA has been found to provide a range of advantages, including developing new therapeutic approaches, optimizing individual medicinal products, and preventing disease.

• In August 2020, a team of researchers at The University of California, Los Angeles (UCLA) and V.A. San Diego Health System (VAHS) employed transcriptome and Antigen Receptor Sequencing (ARS) assays to identify tissue and immune cell characteristics in patients with and without ulcers.

DRIVING FACTORS

Increasing Prevalence of Disease Leads to Large Patient Pool Undergoing Treatment, Driving the Market Growth

Ulcerative colitis and Crohn's disease are two diseases under inflammatory bowel disease, and the prevalence of these diseases is increasing due to various factors, such as genetic predisposition, environmental triggers, and immune system disorders. Increasing prevalence is likely to surge the demand for effective therapeutic solutions for its treatment, and to meet this growing demand, market players are making strategic alliances to focus on accelerating the development of their pipeline drugs.

• For instance, in October 2023, Teva Pharmaceutical Industries Ltd. collaborated with Sanofi to co-develop and co-commercialize TEV ‘574, a novel anti-TL1A therapy, which is under Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn’s disease.

Moreover, government bodies are introducing various initiatives to increase awareness about these diseases by educating them about their symptoms, diagnosis, and treatment options available for them. Therefore, the increasing awareness about treatment options and the growing prevalence of diseases across the country is expected to drive the U.S. market growth in the coming years.

Request a Free sample to learn more about this report.

According to an article published by Medscape in March 2023, about 1 million people are affected with ulcerative colitis in the U.S. The annual incidence rate is 10.4-12 cases per 100,000 population, and the prevalence rate is 35-100 cases per 100,000 population.

RESTRAINING FACTORS

High Medication Costs are Likely to Restrict the Market Growth

High medication costs lead to an increase in the economic burden of the patient population. This may lead to non-adherence and mortality due to the inability to afford, which is anticipated to hamper the demand for these drugs. These chronic diseases cause lifelong burden and often needs sustainable treatment throughout a patient’s life. Pharmaceutical drugs are major factors that affect the costs of inflammatory bowel disease treatment, and the increased use of biologics has raised the total treatment costs.

• For instance, as per a study published by the Inflammatory Bowel Diseases in July 2021, out of approximately 3.1 million adults with IBD in the U.S., 23% reported financial hardships due to medical bills, 16% of patients reported cost-related medication non-adherence and 31% reported cost-reducing behaviors. Furthermore, approximately 62% of patients reported personal or health-related financial distress and 10% of patients deemed health care unaffordable.

Medications, such as anti-inflammatory, are prescribed to lower inflammation and to control the immune system responses. TNF inhibitors are one of the most expensive drug classes, which increases the economic burden on patients and reduces their adherence to complete or continue the inflammatory bowel disease treatment regime. All these factors are limiting the demand for these therapeutics, which is restricting the U.S. market growth.

SEGMENTATION

By Disease Indication Analysis

On the basis of disease indication, the market is segmented into Crohn's disease and ulcerative colitis.

The Crohn’s disease segment dominated the U.S. inflammatory bowel disease treatment market share in 2022. The segment’s growth is attributed to the increasing prevalence and diagnosis rate of this disease, which is likely to drive the demand for inflammatory bowel disease treatment. Moreover, the market players are actively investing in accelerating the development of their pipeline candidates for this indication. The growing focus of market players in getting regulatory approvals to expand the inflammatory bowel disease treatment options for this disease is anticipated to drive the segment’s growth.

• Abbvie Inc. announced the discovery and structure of the Anti-Tumor Necrosis Factor (TNF), Glucocorticoid Receptor Modulator (GRM), Immunology Antibody-Drug Conjugate (iADC) ABBV-154 in April 2023. This drug is currently in Phase II Clinical Development as a subcutaneous treatment for rheumatoid arthritis, polymyalgia rheumatica, and subcutaneous or intravenous treatment for active Crohn's disease.

By Route of Administration Analysis

By route of administration, the market is divided into oral and injectables.

The injectables segment held a larger share of the U.S. market in 2022. The growing adoption of biologics for the treatment of ulcerative colitis and Crohn’s disease is driving the demand for drugs administered through the parenteral route. Clinical benefits offered by this route, such as quick absorption with a rapid onset of action and increasing approval of products, are contributing to the segment’s growth.

• In June 2022, Abbvie Inc. received the U.S. FDA approval for Skyrizi, an injectable selective p19 anti-interleukin (IL)-23 inhibitor, which is indicated to treat moderate to severely active Crohn’s disease. 

By Drug Class Analysis

Based on drug class, the market is classified into IL Inhibitors, TNF inhibitors, anti-integrin, JAK Inhibitors, corticosteroids, ASA drugs, and others.

The TNF inhibitors segment accounted for the majority of the market share. This segment’s growth is driven by the increasing use of monoclonal antibodies for the induction and maintenance of remission in inflammatory bowel disease patients. Furthermore, key market players are focusing on developing drugs classified under TNF inhibitors, which is contributing to the segment's growth.

• According to a study published by the Journal of Clinical Medicine in March 2023, the first biologics approved for this indication were anti-TNFs or TNF inhibitors, which remain among the most effective agents. Furthermore, infliximab (IFX) and Adalimumab (ADA) were the highest-ranked first-line treatments in CD and UC patients for induction of clinical remission, providing a clear advantage over other therapies.

By Distribution Channel Analysis

By distribution channel, the market is segmented into hospital pharmacy and retail pharmacy & other.

The hospital pharmacy segment dominated the U.S. inflammatory bowel disease treatment market with a significant share owing to well-established reimbursement policies across the country, which cover the high cost of these drugs. The prevalence of the condition is increasing due to a lack of adherence and rising ignorance of the patient population toward seeking inflammatory bowel disease treatment. Moreover, this lack of adherence and refusal of the patient population leads to delays or slows down the treatment's progress. This is increasing the hospital admissions rate, and the insurance coverage offered in these settings on the treatment cost is influencing patient’s preference toward this setting, which is subsequently driving the segment's growth.

• As per a study published by WebMD in 2023, the claims related to inflammatory bowel disease are covered by private insurance and Medicare advantage of around USD 23,000 annually.

KEY INDUSTRY PLAYERS

The U.S. market is highly concentrated, with a few major players dominating the market. Abbvie Inc. holds a dominant position in the market with a robust portfolio of biologic drugs for treating ulcerative colitis and Crohn's disease. The company's strong penetration across major geographic regions has made it a market leader globally. For instance, in October 2023, AbbVie Inc. presented new data from the studies of risankizumab (SKYRIZI) in Crohn's disease and upadacitinib (RINVOQ) in ulcerative colitis and Crohn's disease at the United European Gastroenterology (UEG). Such initiatives help in increasing product awareness and in establishing a strong brand presence.

Other prominent players in this market are Takeda Pharma Company Limited, Celgene CORPORATION, and Johnson & Johnson Services, Inc. New product introductions and mergers & acquisitions (M&A) by these key players are helping them to dominate the market. For instance, in September 2022, Takeda Pharmaceutical Company Limited launched the CDPATH program, which includes an innovative, validated personalized prognostic tool that uses blood tests to help in the prediction of the potential risk of developing severe Crohn’s disease-related complications within three years.

LIST OF KEY COMPANIES PROFILED:

• AbbVie Inc. (U.S.)


• Takeda Pharmaceutical Company Limited (Tokyo)


• UCB S.A. (Belgium)


• Bausch Health Companies Inc. (Canada)


• Bristol-Myers Squibb Company (U.S.)


• Pfizer Inc. (U.S.)


• CELLTRION INC. (South Korea)


• Johnson & Johnson Services, Inc. (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• September 2023 – The U.S. Food and Drug Administration (FDA) accepted a Biologics License Application (BLA) for the investigational subcutaneous (SC) administration of ENTYVIO (vedolizumab) of Takeda Pharmaceutical Company Limited for maintenance therapy in adults with moderately to severely active Crohn’s disease.


• July 2023 – Coherus BioScience, Inc., launched the lowest listed price for adalimumab biosimilar YUSIMRY (adalimumab-aqvh) offering in the U.S.


• July 2022 – Athos Therapeutics entered into a research collaboration with Lahey Hospital and Medical Center in Burlington, Massachusetts, for precision medicine in inflammatory bowel disease.

REPORT COVERAGE

An Infographic Representation of U.S. Inflammatory Bowel Disease Treatment Market

View Full Infographic

To get information on various segments, share your queries with us

The U.S. inflammatory bowel disease treatment market report provides a detailed analysis of the market. It focuses on key aspects such as the prevalence of crohn’s disease and ulcerative disease in the U.S. Additionally, it includes an average length of therapy, pricing and margin analysis, pipeline analysis, key industry developments, and the impact of COVID-19 on the market. Besides this, the report also offers insights into the market trends and highlights key industry dynamics. In addition to the aforementioned factors, it encompasses several factors that have contributed to the market growth over recent years.

Report Scope & Segmentation